- Home
- DYAI vs ACXP Comparison
DYAI vs ACXP Comparison
Compare DYAI & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- ACXP
- Stock Information
- Founded
- DYAI 1979
- ACXP 2017
- Country
- DYAI United States
- ACXP United States
- Employees
- DYAI N/A
- ACXP N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- ACXP Health Care
- Exchange
- DYAI Nasdaq
- ACXP Nasdaq
- Market Cap
- DYAI 31.5M
- ACXP 31.4M
- IPO Year
- DYAI 2004
- ACXP 2021
- Fundamental
- Price
- DYAI $1.13
- ACXP $1.72
- Analyst Decision
- DYAI Strong Buy
- ACXP Strong Buy
- Analyst Count
- DYAI 1
- ACXP 1
- Target Price
- DYAI $6.00
- ACXP $12.00
- AVG Volume (30 Days)
- DYAI 18.7K
- ACXP 39.1K
- Earning Date
- DYAI 11-12-2024
- ACXP 11-12-2024
- Dividend Yield
- DYAI N/A
- ACXP N/A
- EPS Growth
- DYAI N/A
- ACXP N/A
- EPS
- DYAI N/A
- ACXP N/A
- Revenue
- DYAI $3,364,548.00
- ACXP N/A
- Revenue This Year
- DYAI $2.04
- ACXP N/A
- Revenue Next Year
- DYAI $110.34
- ACXP N/A
- P/E Ratio
- DYAI N/A
- ACXP N/A
- Revenue Growth
- DYAI 13.82
- ACXP N/A
- 52 Week Low
- DYAI $0.93
- ACXP $1.52
- 52 Week High
- DYAI $2.67
- ACXP $5.28
- Technical
- Relative Strength Index (RSI)
- DYAI 52.65
- ACXP 28.13
- Support Level
- DYAI $1.02
- ACXP $1.82
- Resistance Level
- DYAI $1.23
- ACXP $1.89
- Average True Range (ATR)
- DYAI 0.09
- ACXP 0.08
- MACD
- DYAI 0.01
- ACXP -0.01
- Stochastic Oscillator
- DYAI 52.33
- ACXP 28.10
About DYAI Dyadic International Inc.
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.